| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial (NCT04539366) | National Cancer Institute (NCI) | 2022-01-25 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (NCT04751383) | National Cancer Institute (NCI) | 2021-08-31 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702) | St. Jude Children's Research Hospital | 2021-06-09 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548) | National Cancer Institute (NCI) | 2021-05-11 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults (NCT04530487) | M.D. Anderson Cancer Center | 2020-08-19 |
| Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (NCT03794349) | Children's Oncology Group | 2019-07-08 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (NCT03210714) | National Cancer Institute (NCI) | 2018-06-05 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652) | National Cancer Institute (NCI) | 2018-04-17 |
| Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 (NCT03209869) | University of Wisconsin, Madison | 2018-03-12 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035) | National Cancer Institute (NCI) | 2017-11-08 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03213691) | National Cancer Institute (NCI) | 2017-10-30 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma (NCT03057626) | Children's Oncology Group | 2017-06-05 |
| Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (NCT02641314) | University of Cologne | 2016-12-22 |
| Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (NCT02452554) | Children's Oncology Group | 2015-10-12 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (NCT02173093) | University of Virginia | 2014-11-01 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02011126) | Children's Oncology Group | 2014-06-30 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02095132) | National Cancer Institute (NCI) | 2014-03-28 |
| Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (NCT01767194) | National Cancer Institute (NCI) | 2013-02-12 |
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (NCT01711554) | National Cancer Institute (NCI) | 2013-02-04 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (NCT01334515) | Children's Oncology Group | 2011-09-01 |
| Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma (NCT01358617) | Children's Oncology Group | 2011-05-01 |
| Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma (NCT01208454) | National Cancer Institute (NCI) | 2010-12-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (NCT00939770) | Children's Oncology Group | 2009-09-21 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (NCT00831844) | National Cancer Institute (NCI) | 2009-01-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma (NCT00567567) | Children's Oncology Group | 2007-11-05 |
| Study of DNA in Blood Samples From Patients With Neuroblastoma (NCT00898391) | Children's Oncology Group | 2007-06-01 |
| Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (NCT00638898) | City of Hope Medical Center | 2007-02-26 |
| ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment (NCT00436852) | Children's Oncology Group | 2007-01-01 |
| Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions (NCT00436696) | Children's Oncology Group | 2006-12-11 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors (NCT00331643) | National Cancer Institute (NCI) | 2006-04-01 |
| Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant (NCT00309907) | Children's Oncology Group | 2006-04-01 |
| Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia (NCT00217412) | National Cancer Institute (NCI) | 2005-08-01 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (NCT00101270) | National Cancer Institute (NCI) | 2005-03-01 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (NCT00091182) | National Cancer Institute (NCI) | 2004-10-01 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (NCT00093821) | National Cancer Institute (NCI) | 2004-09-01 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors (NCT00077454) | National Cancer Institute (NCI) | 2004-02-01 |
| Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma (NCT00075634) | National Cancer Institute (NCI) | 2003-12-01 |
| Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma (NCT00053326) | National Cancer Institute (NCI) | 2003-05-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma (NCT00054405) | National Cancer Institute (NCI) | 2002-12-01 |
| Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma (NCT00053950) | National Cancer Institute (NCI) | 2002-12-01 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood (NCT00030667) | National Cancer Institute (NCI) | 2002-05-01 |
| R(+)XK469 in Treating Patients With Advanced Neuroblastoma (NCT00028522) | National Cancer Institute (NCI) | 2001-12-01 |
| Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (NCT00026312) | National Cancer Institute (NCI) | 2001-10-26 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (NCT00012181) | National Cancer Institute (NCI) | 2001-04-01 |
| Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma (NCT00005576) | National Cancer Institute (NCI) | 2001-01-01 |
| Irinotecan in Treating Children With Refractory Solid Tumors (NCT00004078) | Children's Oncology Group | 1999-10-01 |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma (NCT02075177) | South Plains Oncology Consortium | |